
Mac & Cheese Recall Update as FDA Issues Risk Warning
Louisa Food Products, Inc., based in Saint Louis, Missouri, initiated a voluntary recall on July 17 for a select lot of its Breaded Jalapeno Mac & Cheese Bites after a supplier recalled an ingredient that was potentially contaminated with Listeria monocytogenes.
The FDA later issued a Class II risk classification for the recall on August 6.
Newsweek contacted Louisa Food Products, Inc. for comment via its website outside of regular working hours.
A Class II risk classification (one of three) refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA.
Listeria infection, or listeriosis, may lead to a range of symptoms in infected individuals. For those experiencing less severe infections, symptoms may include fever, muscle aches, nausea, vomiting and diarrhea, which often last between one and three days, the FDA said.
For more severe and potentially life-threatening infections, symptoms may include headaches, stiff neck, confusion, loss of balance and convulsions.
Severe infections are particularly dangerous for young children, frail or elderly people, and those with weakened immune systems. It can also lead to miscarriages and stillbirths in pregnant women.
The product affected by the recall is the company's "Breaded Jalapeno Mac & Cheese Bites." According to the FDA, 819 cases are being recalled with the item number 90935 and lot code 2407092.
The product was distributed to retail locations in Delaware and Illinois.
No illnesses have been reported so far in connection with the consumption of the recalled product.
Mary O'Riordan, a professor of microbiology and immunology at the University of Michigan Medical School, previously told Newsweek: "Listeria has an unusual capacity to grow at refrigerated temperatures. Although the bacterium can contaminate many types of food, cheeses or deli meats that are kept in cold storage for long periods in stores or at home are a place where listeria can keep growing.
"Early symptoms of listeria infection look similar to other common foodborne infections, including fever, diarrhea and vomiting, so it's often not diagnosed right away. Unfortunately, sometimes listeria can spread into the brain and cause more serious illness, like meningitis. In those cases, if people experience headache, stiff neck or confusion, they should seek urgent medical attention."
Haley F. Oliver, a professor of food science at Purdue University, previously told Newsweek: "Listeria monocytogenes is a common microorganism that can be found in the natural environment, for example in soil. There are many factors that determine if someone gets listeriosis—a listeria infection. In most instances, an immunocompromised person—so young, old, pregnant or otherwise immunocompromised—must eat contaminated food. The number of bacteria resulting in infection and the amount of time before illness varies considerably. Symptoms vary among people but can include fever, flu-like symptoms, headache, stiff neck, confusion and loss of balance."
The FDA says on its website: "Pregnant women and their unborn or newborn baby, adults over the age of 65, and those with weakened immune systems, are all considered to be high-risk groups that are susceptible to the serious and adverse effects of listeriosis."
The recall is listed as ongoing, according to the FDA. Consumers who purchased the product should not consume it.
Related Articles
Tea Recalled Nationwide as FDA Sets Risk LevelFDA Issues Highest Risk Warning for Fruit Recalled Across the USIce Cream Recall Map Shows States With New Warning
2025 NEWSWEEK DIGITAL LLC.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™
TechLive™ is a vendor-agnostic integrated solution enabling remote scanning of MR, CT, PET/CT, and Ultrasound procedures Amidst radiology technologist shortages, remote scanning in a command center configuration enables the workforce to scan at multiple locations simultaneously with a high level of expertise RadNet has connected more than 300 MR, CT, PET/CT, and Ultrasound systems with TechLive™, delivering operational efficiency and increased access to advanced procedures LOS ANGELES and SOMERVILLE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and global leader in AI-powered health informatics, announced today that it has received FDA 510(k) clearance for TechLive™ - a remote scanning solution enabling centralized operation and supervision of MR, CT, PET/CT, and Ultrasound procedures. Amidst tech labor shortages and inflationary wage pressure, TechLive™ empowers technologists to scan for multiple locations, enables improved operational efficiency, extends center operating hours, and enhances access to complex procedures. More than 300 of RadNet's MR, CT, PET/CT, and Ultrasound systems are now connected with DeepHealth's TechLive™ solution, resulting in increased patient throughput and improved quality through remotely matching expert staff with complex modalities in real-time. Over the past decade, radiology workloads have steadily increased, while the number of qualified technologists have not grown proportionally. In a pilot deployment at 64 locations inside of RadNet's New York area facilities, TechLive™ significantly contributed to a 42% decrease in MRI room closure hours during the second quarter of 2025 as compared with the same period in 2024, allowing more patients to receive timely scans. Additionally, as a result of the remote expert involvement during the same pilot deployment, TechLive™ contributed to an increase in complex procedures. Furthermore, in extending remote scanning capabilities to Ultrasound, TechLive™ is enabling experienced senior sonographers and physicians to remotely guide technologists on-site through complex cases in a modality that is heavily dependent upon real-time, operator expertise. "TechLive™ represents a paradigm shift in how we approach imaging operations," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. "By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries." About DeepHealthDeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth, Kheiron, and iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. About RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit DeepHealth ContactAndra AxenteDirector of Communications+ RadNet, Inc. ContactMark StolperExecutive Vice President and Chief Financial Officer310-445-2800 Forward-Looking Statements This communication contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'possible,' 'predict,' 'project,' 'seek, 'should,' 'target,' 'will' or 'would,' the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the streamlining of delivery and deployment across healthcare facilities, and TechLive creating a foundation for more efficient, financially sustainable and high-quality patient care across the broadest set of imaging modalities, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet's control. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of RadNet's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet's control. RadNet's actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet nor its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet's business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's filings with the Securities and Exchange Commission (the 'SEC'), including the risk factors discussed in RadNet's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC. Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.


New York Post
6 hours ago
- New York Post
FDA pulls popular ice cream from shelves after packaging mix up: ‘Serious allergic reaction'
Ice cream lovers may have more than a meltdown. Friendly's Ice Cream has recalled one of its most popular flavors after a packaging mix up sparking an allergy risk warning from the Food and Drug Administration, which who said it could cause 'a serious or life-threatening allergic reaction.' DFA Dairy Brands, LLC, voluntarily pulled 324 cartons of its 48-fluid-ounce Friendly's Cookies & Cream ice cream from stores after they were packaged in Vanilla Bean containers but topped with Cookies & Cream lids, the FDA said. 3 Friendly's Ice Cream their Cookies & Cream ice cream from stores across the nation. Paul Weaver/SOPA Images / Shutterstock The Vanilla Bean flavor does not contain soy or wheat, which are present in Cookies & Cream. Therefore, the Vanilla Bean cartons don't list those ingredients, according to the FDA. 'For many people, a reaction to soy or wheat usually means abdominal pain, but you could get a rash, or less commonly, asthma-like symptoms,' said Dr. Joseph Raduazzo, an internal medicine specialist in Massachusetts. 3 Federal officials are warning that the mislabeling could have deadly consequences for allergy sufferers. friendlys 'For people with a severe allergy to soy or wheat, the reaction could be life-threatening, similar to when people with peanut allergies come into contact with the nut.' No illnesses or adverse reactions have been reported due to the mispackaging, according to the FDA website. The recalled ice cream was distributed through a single distribution center, UNFI, to retail stores in Maryland, Virginia and Pennsylvania, the agency said. 3 The recall was issued due to the Food and Drug Administration saying in what was a package mix-up that the 324 cartons of ice cream posed an allergy risk that can cause 'a serious or life-threatening allergic reaction.' REUTERS No other Friendly's products were included, a recorded message on a Friendly's consumer hotline said. Last month, Florida-based Rich's Ice Cream recalled over 100,000 ice cream bars in 23 states – including New York and Pennsylvania – due to listeria concerns. The voluntary removal from the market was one of the largest ice cream recalls in recent history.


Buzz Feed
7 hours ago
- Buzz Feed
Kim Kardashian Stem Cell Treatment Post Draws Ire
Kim Kardashian is under fire after promoting an expensive stem cell treatment. In an Aug. 8 Instagram post, Kim talked about traveling to Mexico to receive stem cell therapy to treat "debilitating pain" caused by a shoulder injury from lifting weights two years ago. According to her, she'd "tried everything to find relief" before visiting Dr. Adeel Khan at Eterna Health and achieving "immediate" results. Kim said, "I regained full range of motion, and my shoulder has felt completely normal ever since." The positive experience led her to return to Dr. Khan "to address chronic back pain that I have been suffering with for years." Kim shared, "The Muse stem cell treatment was a game-changer once again. I experienced relief right away, and the unbearable pain is finally gone." She highly recommended the treatment for anyone struggling with back pain, writing, "It's transformed my life when I thought my body was breaking down." Except, for many people, stem cell treatment is wildly unaffordable. According to Global Stem Cell Therapy, costs in Mexico can be anywhere between $4,000 and $15,000. On top of that, many stem cell treatments are not FDA-approved, including those for shoulder and back pain. That said, many people weren't feeling Kim's post. This person straight-up told her, "Kimmy we're poor." Another commented, "Kim, there's people that are dying." Others wished they had that luxury... ...And accepted they'll have to live with their pain forever because they aren't rich. Another person sarcastically said, "Sounds super affordable." As others pointed out how wildly out-of-touch Kim's post was in the current economy. You can see more comments below, and then let me know what you think in the comments.